Clinical significance of basic fibroblast growth factor in patients with multipal myeloma

Objective To study the expression of basic fibroblast growth factor(bFGF) and its clinical significance in multipal myeloma(MM). Methods Serum levels of bFGF in 41 patients with MM were measured by ELISA method and compared with those of normal controls. The associations were observed among bFGF levels,MM stages(Ⅰ-Ⅲ), and curative effect. Results Serum levels(70.53±21.88) of bFGF in patients with MM were higher significantly than those(22.96±7.13) in normal controls(P0.01). Serum levels(78.14±40.52) of bFGF in patients with Ⅲ stage were higher significantly than those(47.05±24.87) in Ⅱ stage, and (39.28±21.53) in Ⅰ stage (P0.05), but the difference between Ⅰ stage and Ⅱ stage was not significant(P0.05). The differences of bFGF levels in different tumor load were found(P0.05). Serum bFGF levels in patients of CR decreased obviously after treatment(P0.01), but those in PR,SD and PD changed little(P0.05). No difference was found between different groups according to bone lesion scores.Conclusion Serum bFGF may be an useful item for detecting clinical features and predicting prognosis of MM patients.